In recent years, it has been reported that immune checkpoint inhibitors (ICIs, i.e., PD-L1 inhibitors) have a certain effect in the treatment of glioma (Ampudia-Mesias et al., 2021). This evidence concerns the gene CD274 and central nervous system cancer.